When Will Retatrutide Be Available? A Realistic Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · Author: FormBlends Editorial

Key Takeaways

• Retatrutide is investigational and not FDA-approved as of May 2026. FormBlends does not sell, supply, or formulate retatrutide. This page is educational.
• The earliest plausible U.S. availability is late 2027 if TRIUMPH-1 reports in late 2026 with strong results and Lilly secures priority FDA review.
• A more conservative expectation is mid-2028 to early 2029, allowing for standard review timelines, manufacturing scale-up, and the typical lag between approval and broad availability.
• The tirzepatide approval pathway is the closest analog. Tirzepatide reported phase 3 obesity data (SURMOUNT-1) in May 2022 and received FDA approval for obesity (Zepbound) in November 2023, a gap of about 18 months.
• Compounded retatrutide will not be legally available at launch. Insurance coverage will take 6-18 months to develop after approval. Patients hoping for retatrutide in 2026 are several years early.

Direct answer

Retatrutide will not be available in 2026. The earliest plausible U.S. availability is late 2027, assuming the TRIUMPH-1 phase 3 obesity trial reports on schedule, the data supports an FDA submission, the agency grants priority review, and the review concludes without complete response letters. A more conservative expectation is mid-2028 to 2029. Approval and broad availability are different things: cash-pay access typically precedes insurance coverage by 6-18 months.

Table of contents

1. What "available" actually means
2. The TRIUMPH phase 3 readout schedule
3. Modeling the path from readout to approval
4. The tirzepatide analog
5. The semaglutide analog
6. What could accelerate the timeline
7. What could slow the timeline
8. Approval is not the same as broad availability
9. What about compounded retatrutide
10. The contrary view: should patients pin hope on a 2027 launch
11. The decision framework while you wait
12. FAQ
13. Sources

What "available" actually means

The "available" question hides three different milestones that arrive in sequence:

1. FDA approval. The regulatory go-ahead. Approval itself does not put pills on shelves.
2. Commercial launch. Manufacturing, distribution, and pharmacy stock. Typically 1-3 months after approval for major sponsors.
3. Broad patient access. Insurance coverage, prior authorization workflows, manufacturer savings programs, and supply at scale. Typically 6-18 months after launch.

For retatrutide, the question "when will it be available" therefore has at least three answers depending on what you mean. The earliest-availability answer (you can theoretically obtain it through cash pay at a major pharmacy) is meaningfully earlier than the broad-availability answer (your insurance is reliably covering it).

The TRIUMPH phase 3 readout schedule

Selected major TRIUMPH trials per ClinicalTrials.gov registry information accessible in May 2026:

Trial	Population	Estimated primary completion	Estimated full readout
TRIUMPH-1	Adults with obesity or overweight, no diabetes	Late 2026 to early 2027	Within months of primary completion
TRIUMPH-2	Adults with type 2 diabetes and obesity	2027	Within months of primary completion
TRIUMPH-3	Cardiovascular outcomes trial	2028-2030 (event-driven)	Years after primary completion
TRIUMPH-4	Obstructive sleep apnea	2027	Within months
Hepatic steatosis trial	MAFLD/MASH	2027-2028	Within months

TRIUMPH-1 is the trial most likely to support the initial FDA submission. The other trials would support label expansions for additional indications after the primary obesity approval.

Cardiovascular outcomes data from TRIUMPH-3 is not required for the initial obesity approval, although it would strengthen the regulatory and clinical case. TRIUMPH-3 is event-driven (the trial continues until a predetermined number of cardiovascular events occur), which is why the primary completion estimate is wide.

Modeling the path from readout to approval

Building a realistic timeline from TRIUMPH-1 readout to retatrutide on pharmacy shelves:

Step	Typical duration	Cumulative timing from late 2026 readout
TRIUMPH-1 primary completion	Reference point	Late 2026
Lilly internal data review and submission preparation	3-6 months	Q1-Q2 2027
NDA submission to FDA	Single event	Q2-Q3 2027
FDA filing acceptance review	2 months	Q3-Q4 2027
FDA priority review (if granted)	6-8 months	Q1-Q3 2028
FDA standard review	10-12 months	Q3 2028 to Q1 2029
Approval and labeling	Single event	2028 (best case) or 2029
Commercial launch	1-3 months post-approval	Late 2028 or 2029
Insurance coverage decisions	6-18 months post-launch	Mid-2029 to early 2030

The aggressive best-case timeline (TRIUMPH-1 reads out late 2026 with strong results, fast Lilly submission, FDA priority review with no complete response letter, fast commercial launch): retatrutide on shelves in late 2027 or early 2028.

The conservative timeline (some slippage in trial completion, standard FDA review, normal launch logistics): retatrutide on shelves in mid-2029 with broad insurance coverage by 2030.

The tirzepatide analog

The most useful real-world reference for predicting retatrutide's timeline is tirzepatide, since both are Lilly incretins moving through phase 3 to approval.

Milestone	Tirzepatide date	Implication for retatrutide
SURPASS phase 3 readouts (T2D)	Starting 2021	Phase 3 readouts are a clear regulatory trigger
FDA approval for T2D (Mounjaro)	May 2022	~14 months from major readout to approval
SURMOUNT-1 obesity readout	April 2022	Reference point
FDA approval for obesity (Zepbound)	November 2023	~19 months from SURMOUNT-1 to obesity approval
Commercial launch (Zepbound)	Late November 2023	Approval-to-launch was rapid
Broad insurance coverage	Throughout 2024	~6-12 months post-launch

Applying the tirzepatide timeline to retatrutide: if TRIUMPH-1 reports in late 2026, retatrutide obesity approval following the tirzepatide pattern would land mid-2028, with commercial launch immediately following and broad coverage developing through 2029.

Two factors could compress this. First, Lilly's regulatory operations have matured since the tirzepatide submissions and may move faster on retatrutide. Second, FDA priority review (granted to Wegovy but not Zepbound) could shorten the agency review by 4-6 months if granted.

The semaglutide analog

Semaglutide's path to obesity approval offers a different reference point.

• Semaglutide approved for T2D (Ozempic) in December 2017
• STEP 1 obesity trial reported in 2021
• Semaglutide approved for obesity (Wegovy) in June 2021, with priority review
• Commercial launch and supply constraints throughout 2022-2023

The semaglutide obesity approval was relatively fast (priority review) but launched into immediate supply constraints that took two years to fully resolve. If retatrutide follows a similar pattern, the early-launch period may have meaningful supply limitations.

Eli Lilly has invested significantly in manufacturing capacity through 2024-2026 partly to avoid the supply problems Novo Nordisk faced with Wegovy. Retatrutide manufacturing should benefit from this preparation. But the demand pull for a drug producing 24% mean weight loss could be larger than anything in incretin history.

What could accelerate the timeline

FDA Breakthrough Therapy designation. Not publicly granted to retatrutide as of May 2026. If granted later, it would entitle the program to more frequent FDA interaction and potentially priority review.

Priority review designation. FDA can grant priority review (6-8 month target) instead of standard review (10-12 month target) for drugs offering significant improvement over existing therapies. Retatrutide's mean weight loss exceeds approved alternatives, supporting priority review eligibility.

Smaller submission package. If FDA agrees to accept TRIUMPH-1 alone for the obesity indication, the submission is leaner and faster. If the agency requires data from multiple TRIUMPH trials, submission delays.

Manufacturing readiness. Lilly's investment in incretin manufacturing capacity since 2023 may allow earlier commercial launch immediately after approval.

Strong, clean phase 3 data. A clean dataset reduces back-and-forth with FDA during review.

What could slow the timeline

Phase 3 efficacy or safety surprise. Lower-than-phase-2 efficacy, unexpected adverse event signals, or cardiovascular concerns from emerging TRIUMPH-3 data could prompt additional trials or label restrictions.

FDA complete response letter. If the agency identifies deficiencies during review, the sponsor must address them before approval. CRLs can add 6-24 months.

Manufacturing inspection issues. FDA inspects manufacturing facilities before approval. Issues can delay approval until resolved.

Heart rate signal scrutiny. The phase 2 heart rate increase may prompt FDA to require additional cardiovascular safety data, potentially through TRIUMPH-3 interim analysis, before granting approval.

Pediatric label commitments. FDA typically requires pediatric study commitments for new drugs in adults. Retatrutide's pediatric program is at an earlier stage; delays in committing to a pediatric plan could extend the regulatory negotiation.

Black-box warning requirement. If FDA requires a boxed warning beyond the standard thyroid C-cell tumor language, label negotiation can add time.

Approval is not the same as broad availability

Patients planning around retatrutide should distinguish between approval, launch, and broad access.

Approval. The regulatory go-ahead. The product exists legally but is not yet on shelves.

Commercial launch. Manufacturing complete, distribution active, pharmacy stock available. Typically 1-3 months after approval for major sponsors. Cash-pay or manufacturer-direct purchase usually available at launch.

Insurance coverage decisions. Insurers typically take 6-18 months to develop formal coverage policies for new drugs in established categories. Initial coverage may require step therapy (trying other drugs first) or prior authorization.

Broad real-world access. Most eligible patients can access the drug through insurance with manageable administrative burden. Typically 18-36 months after launch.

For retatrutide, this means the timeline for "available" could be:

• Approved: 2027-2028
• Launched (cash pay or manufacturer direct): immediately after approval
• Insurance coverage developing: 2028-2030
• Broad real-world access: 2029-2031

Patients who can afford cash-pay at $1,000-1,300 per month list price (the comparable range for Zepbound at launch) will access retatrutide significantly earlier than patients waiting for insurance coverage.

What about compounded retatrutide

This deserves a dedicated section because the question recurs.

Compounded retatrutide will not be legally available at the time of brand launch. The legal compounding framework requires the active pharmaceutical ingredient to be either an FDA-approved drug or on the FDA bulk drug substance permitted list. Retatrutide will be neither until approval, and after approval, it would need to enter a shortage designation before 503A compounding becomes broadly permitted.

Two scenarios could change this:

1. Approval plus shortage designation. If retatrutide is approved and demand exceeds initial supply (likely given the expected interest), FDA may add it to the shortage list. Compounding would then be permitted under specific conditions, similar to what happened with semaglutide and tirzepatide.
2. Bulk substance list addition. Less likely. FDA's bulk substance permitted list is short and conservative. New additions are uncommon and slow.

Patients hoping to access compounded retatrutide should not expect availability until at least 12-24 months after approval, if at all. The semaglutide shortage that allowed compounding lasted from 2022 to 2024 and is now ending. Tirzepatide is exiting shortage. The legal compounding window for new incretins may be narrower than it was in 2022-2024.

FormBlends works with 503A compounding pharmacies that follow federal regulations. We do not anticipate offering compounded retatrutide unless and until federal compounding regulations explicitly permit it.

The contrary view: should patients pin hope on a 2027 launch

The case against optimistic retatrutide timeline expectations:

Argument 1: Phase 2 to phase 3 effect-size attenuation. Phase 3 results sometimes shrink compared to phase 2. If TRIUMPH-1 shows 19% mean weight loss instead of 24%, the regulatory and commercial story changes substantially. Approval still likely, but the comparison to tirzepatide becomes less compelling.

Argument 2: Cardiovascular caution. The phase 2 heart rate signal is real. FDA may require interim cardiovascular safety data from TRIUMPH-3 before granting approval, even though TRIUMPH-3 is event-driven and slow. This could delay the obesity approval by 1-3 years.

Argument 3: Manufacturing complexity. Triple agonists are more complex peptides than dual or single agonists. Scale-up to commercial manufacturing volumes may face challenges Lilly has not yet publicly characterized.

Argument 4: The base rate is unfriendly. Across pharmaceutical history, only a fraction of phase 3 programs result in approval within 2 years of major readouts. Retatrutide is more likely to meet timelines than the average phase 3 program, but the base rate suggests caution.

The counter-counter: Lilly has executed efficient regulatory processes on tirzepatide. Retatrutide's clinical case is exceptionally strong. The FDA has shown willingness to act quickly on incretin obesity approvals when data supports them. None of the structural factors that would slow retatrutide are unique to this program.

The honest synthesis: 2027 is plausible but not assured. 2028 is more likely. 2029 or later is realistic if any major delay occurs. Anyone planning their health around retatrutide availability should plan for 2028 and treat earlier availability as a bonus.

The decision framework while you wait

If you have obesity and have not started any incretin therapy:

• Approved options exist. Tirzepatide produces 22.5% mean weight loss at the max dose; semaglutide produces 14.9%. Both are FDA-approved and supported by long-term safety data.
• Starting therapy now produces real benefit. Waiting 2-4 years for retatrutide costs you years of weight loss and metabolic improvement.
• When retatrutide is approved, you can discuss switching with your clinician at that time.

If you are on semaglutide and progressing:

• Continue current therapy.
• Plateau or insufficient response may warrant switching to tirzepatide.
• Retatrutide is not a current option.

If you are on tirzepatide at maximum dose with plateau:

• This is the profile most likely to benefit from retatrutide when available.
• Continue current therapy.
• Discuss clinical trial enrollment with your clinician if you meet eligibility criteria.

If you are considering research peptide retatrutide:

• This is not the same product Lilly is studying.
• Quality is not verified. Safety is unknown.
• Approved alternatives produce substantial weight loss with established safety.

If you want to enroll in a TRIUMPH trial:

• ClinicalTrials.gov lists active TRIUMPH sites.
• Eligibility depends on BMI, comorbidities, and other factors.
• Trial enrollment is the only legal U.S. route to receive retatrutide before approval.

FAQ

When will retatrutide be available? Earliest plausible U.S. availability is late 2027. More likely 2028. Conservative expectation is 2029.

When will retatrutide be FDA approved? Plausible approval window is late 2027 to 2029, depending on phase 3 readout timing, FDA review pathway, and any complete response letters.

When will the TRIUMPH-1 trial finish? Per registry information accessible in May 2026, estimated primary completion is late 2026 to early 2027.

Will retatrutide be available in 2026? No.

Will retatrutide be available in 2027? Possibly in the second half if regulatory and clinical milestones land optimistically. Not likely in the first half.

Will retatrutide be available before insurance covers it? Yes. Approval and launch typically precede broad insurance coverage by 6-18 months. Cash-pay access usually begins at launch.

How much will retatrutide cost? Pricing has not been announced. Comparable Lilly incretins launched at $1,000-1,300 per month list price, with manufacturer savings programs reducing patient out-of-pocket cost.

When will compounded retatrutide be available? Compounded retatrutide cannot be legally produced in the U.S. unless and until retatrutide is approved and enters a shortage designation. Earliest plausible window is 2028-2029, and may not occur at all.

Can I be notified when retatrutide is approved? Eli Lilly has not announced a public notification list. The FDA approval announcement is public and will be covered by major medical news outlets.

What if TRIUMPH-1 fails? Lilly would assess the failure mode and decide whether to continue the program. A failed phase 3 trial typically delays approval by 2+ years if the program continues at all.

Will retatrutide be approved for both obesity and diabetes? Likely both, but probably in sequence. Initial approval is expected for obesity. Diabetes indication would follow based on TRIUMPH-2 data.

How can I prepare for retatrutide when it becomes available? Continue any current incretin therapy. Establish care with a clinician familiar with obesity pharmacotherapy. Verify insurance coverage patterns for current incretins; coverage for retatrutide is likely to follow similar patterns.

Related guides

• When Will Orforglipron Be Available? The Realistic Timeline
• Retatrutide FDA Approval Timeline: When Will It Be Available?
• When Will CagriSema Be Available? Reading the FDA Timeline Honestly
• When Will Retatrutide Be Available? The Four Meanings of "Available" in May 2026
• Will Retatrutide Be Available As a Pill
• Will Compounded Retatrutide Be Available?
• Tool: weight-loss timeline tool

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. June 2023.
2. Rosenstock J et al. Retatrutide for type 2 diabetes: a phase 2 trial. Lancet. 2023.
3. ClinicalTrials.gov. TRIUMPH phase 3 program registry entries. Accessed May 2026.
4. U.S. Food and Drug Administration. Drugs@FDA Approval Database: Tirzepatide (Mounjaro, Zepbound) approval records. Accessed May 2026.
5. U.S. Food and Drug Administration. Drugs@FDA Approval Database: Semaglutide (Ozempic, Wegovy) approval records. Accessed May 2026.
6. U.S. Food and Drug Administration. Priority Review and Breakthrough Therapy Designation Guidance for Industry. Accessed May 2026.
7. U.S. Food and Drug Administration. Drug Shortage Database. Accessed May 2026.
8. Eli Lilly and Company. Investor presentations and pipeline materials. Accessed May 2026.
9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital telehealth platform that connects patients with independent licensed clinicians and U.S. state-licensed pharmacies. FormBlends does not manufacture, prescribe, or dispense medication directly. FormBlends does not sell, supply, formulate, or distribute retatrutide. Retatrutide is investigational and not FDA-approved as of May 2026.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide currently accessible through FormBlends-connected 503A state-licensed compounding pharmacies are prepared in response to individual prescriptions. They are not FDA-approved drugs. Retatrutide is not legally compoundable in the U.S. as of May 2026 and is not available through FormBlends in any form.

Results Disclaimer. Estimated approval timelines reflect best-faith projections based on publicly available trial registry information, the tirzepatide and semaglutide regulatory analogs, and typical FDA review patterns. Actual timelines may differ substantially due to trial outcomes, regulatory decisions, manufacturing scale-up, complete response letters, or other factors outside FormBlends's knowledge or control.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is the international nonproprietary name for an Eli Lilly investigational compound (development code LY3437943) and has no current U.S. brand name. FormBlends is not affiliated with Eli Lilly, Novo Nordisk, the FDA, or any sponsor of the cited clinical trials.